| Literature DB >> 28006013 |
Van Ngoc Bui1,2, Thi Thu Huyen Nguyen3, Chi Thanh Mai1, Yvan Bettarel4, Thi Yen Hoang1, Thi Thuy Linh Trinh1, Nam Hai Truong1, Hoang Ha Chu1, Vu Thanh Thanh Nguyen3, Huu Duc Nguyen5, Stefan Wölfl2.
Abstract
In Vietnam, a great number of toxic substances, including carcinogens and procarcinogens, from industrial and agricultural activities, food production, and healthcare services are daily released into the environment. In the present study, we report the development of novel yeast-based biosensor systems to determine both genotoxic carcinogens and procarcinogens by cotransformation with two plasmids. One plasmid is carrying human CPR and CYP (CYP3A4, CYP2B6, or CYP2D6) genes, while the other contains the RAD54-GFP reporter construct. The three resulting coexpression systems bearing both CPR-CYP and RAD54-GFP expression cassettes were designated as CYP3A4/CYP2B6/CYP2D6 + RAD54 systems, respectively and used to detect and evaluate the genotoxic potential of carcinogens and procarcinogens by selective activation and induction of both CPR-CYP and RAD54-GFP expression cassettes in response to DNA damage. Procarcinogens were shown to be predominantly, moderately or not bioactivated by one of the CYP enzymes and thus selectively detected by the specific coexpression system. Aflatoxin B1 and benzo(a)pyrene were predominantly detected by the CYP3A4 + RAD54 system, while N-nitrosodimethylamine only moderately activated the CYP2B6 + RAD54 reporter system and none of them was identified by the CYP2D6 + RAD54 system. In contrast, the genotoxic carcinogen, methyl methanesulfonate, was detected by all systems. Our yeast-reporter system can be performed in 384-well microplates to provide efficient genotoxicity testing to identify various carcinogenic compounds and reduce chemical consumption to about 53% as compared with existing 96-well genotoxicity bioassays. In association with a liquid handling robot, this platform enables rapid, cost-effective, and high-throughput screening of numerous analytes in a fully automated and continuous manner without the need for user interaction.Entities:
Mesh:
Substances:
Year: 2016 PMID: 28006013 PMCID: PMC5179006 DOI: 10.1371/journal.pone.0168721
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Activity test of recombinant human CPR (A) and recombinant human CYP3A4, CYP2B6, and CYP2D6 (B). 3A4+, 2B6+, and 2D6+ are microsomes of clones coexpressing both CPR and CYP genes; 3A4–, 2B6–, and 2D6– or CPR–are microsomes of clones expressing only one gene, the CYPs or CPR, respectively; NC (negative control) are microsomes of clones bearing the control pESC-URA plasmid. The standard deviation values of the measurements of fluorescence microplate assay (B) were all less than 5% of the calculated values and are thus not presented here.
Fig 2Fluorescence induction in yeast cells transformed with different gene constructs in response to DNA damage.
Yeast-based biosensors were either nontreated (NT, control) or exposed to increasing concentrations of AFB1 (A), BaP (B), NDMA (C), and MMS (positive genotoxin, D). CYP3A4 + RAD54: strain transformed with both CPR-CYP3A4 and RAD54-GFP constructs; RAD54: strain transformed with only the RAD54-GFP construct; NCs (negative control) system: strain transformed with two control pESC-URA and pUMGP5 plasmids. The GFP fluorescence intensity of measurements was compared within linear range of GFP signals by calculation of GFP fold induction. The horizontal dashed line at 1.3 fold GFP induction is used as cutoff or genotoxicity threshold. Other negative (untransformed yeast cells) and process (medium) controls are not presented here.
Analysis and evaluation of fluorescence signals in different yeast strains in response to serial dilution concentrations of test compounds.
| Substance | Concentration | CYP3A4 + RAD54 | CYP2B6 + RAD54 | CYP2D6 + RAD54 | RAD54 | NCs |
|---|---|---|---|---|---|---|
| Aflatoxin B1 | NT | – | – | – | – | – |
| 0.1 μM | + | – | – | – | – | |
| 0.2 μM | ++ | – | – | – | – | |
| 0.4 μM | ++ | + | – | – | – | |
| Benzo(a)pyrene | NT | – | – | – | – | – |
| 10 μM | + | – | – | – | – | |
| 20 μM | + | – | – | – | – | |
| 40 μM | ++ | – | – | – | – | |
| NT | – | – | – | – | – | |
| 10 mM | – | – | – | – | – | |
| 20 mM | – | – | – | – | – | |
| 40 mM | – | + | – | – | – | |
| Methyl methanesulfonate | NT | – | – | – | – | – |
| 25 μM | + | + | + | + | – | |
| 50 μM | +++ | +++ | +++ | +++ | – | |
| 100 μM | ++++ | ++++ | ++++ | ++++ | – |
CYP3A4 + RAD54; CYP2B6 + RAD54; and CYP2D6 + RAD54: Strains transformed with two CPR-CYP and RAD54-GFP expression constructs; RAD54: Strain transformed with only one RAD54-GFP expression construct; NCs (negative control): Strain transformed with two control pESC-URA and pUMGP5 plasmids. Negative (≤1.3 GFP fold induction),–; positive (>1.3 GFP fold induction), + (1.3, 2]; ++ (2, 3]; +++ (3, 4]; ++++ (4, ∞]
Summary and comparison of the results of the present study with the data from published report.
| Substance | Results from the present study | Results from published report (Walsh et al. 2005) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Concentration(μg/mL) | RAD54 | CYP3A4 + RAD54 | CYP2B6 + RAD54 | CYP2D6 + RAD54 | Concentration(μg/mL) | RAD54-GFP integrant | RAD54-GFP integrant + CYP3A4 | RAD54-GFP integrant + CYP1A2 | |
| Aflatoxin B1 | 0.03–0.13 | – | + | + | – | 20–40 | – | Not tested | + |
| Benzo(a)pyrene | 2.52–10.09 | – | + | – | – | Not tested | Not tested | ||
| 0.74–2.96 | – | –* | + | – | 1.56–6.25 | – | + | Not tested | |
| Methyl methane-sulfonate | 2.75–11.01 | + | + | + | + | 1.02–33 | + | + | + |
– or +, negative or positive results; –*, varying results inconsistent with those from the original study of Walsh et al. 2005 [30]
Primer pairs used for construction of plasmids pESC-CPR-CYPs
| Primer name | Sequence (5′-3′) | Size of PCR product (bp) |
|---|---|---|
| CPR-F | 2064 | |
| CPR-R | ||
| CYP3A4-F | 1539 | |
| CYP3A4-R | ||
| CYP2B6-F | 1506 | |
| CYP2B6-R | ||
| CYP2D6-F | 1524 | |
| CYP2D6-R |
The underlined and bold bases are the restriction sites of BamHI (GGATCC) and KpnI (GGTACC); SpeI (ACTAGT) and PacI (TTAATTAA) incorporated in forward (F) and reverse (R) primers for amplification of CPR and CYPs genes (CYP3A4, CYP2B6, and CYP2D6), respectively. The extra bases upstream of the restriction sites are for improvement of cutting efficiency.